Literature DB >> 29678942

Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis.

Christopher Lambers1, Panja M Boehm1, Silvia Lee2, Fabio Ius3, Peter Jaksch1, Walter Klepetko1, Igor Tudorache3, Robin Ristl4, Tobias Welte5,6, Jens Gottlieb5,6.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29678942     DOI: 10.1183/13993003.00503-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

Review 1.  Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.

Authors:  Lutz Wollin; Jörg Hw Distler; Christopher P Denton; Martina Gahlemann
Journal:  J Scleroderma Relat Disord       Date:  2019-04-21

2.  Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?

Authors:  Michael Z L Zhu; Joanna Yilin Huang; David Hongwei Liu; Gregory I Snell
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-01-18

Review 3.  Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.

Authors:  Pilar Rivera-Ortega; Conal Hayton; John Blaikley; Colm Leonard; Nazia Chaudhuri
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

Review 4.  Lung Transplantation in Idiopathic Pulmonary Fibrosis.

Authors:  Rosalía Laporta Hernandez; Myriam Aguilar Perez; María Teresa Lázaro Carrasco; Piedad Ussetti Gil
Journal:  Med Sci (Basel)       Date:  2018-08-23

Review 5.  Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Authors:  Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter
Journal:  Respir Res       Date:  2020-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.